VitriVax is commercializing a vaccine formulation platform enabling thermostability, and combined doses with timed release, for virtually any injectable vaccine. Our proprietary technology, created at the University of Colorado in Boulder with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, more affordable, and more accessible globally.